Identification
NameBrodalumab
Accession NumberDB11776
TypeBiotech
GroupsApproved, Investigational
Description

Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.

Protein structureNo structure small
Related Articles
Protein chemical formulaNot Available
Protein average weightNot Available
SequencesNot Available
SynonymsNot Available
External IDs AMG 827 / AMG-827 / KHK-4827 / KHK4827
Product Ingredients Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
SiliqInjection210 mg/1SubcutaneousValeant Pharmaceuticals North America2017-02-15Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII6ZA31Y954Z
CAS number1174395-19-7
Pharmacology
Indication

Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.

Structured Indications
Pharmacodynamics

Increase in the level of IL-17 due to blocking of its receptors.

Mechanism of action

Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family.

Related Articles
AbsorptionNot Available
Volume of distribution

4.62 L.

Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
Clearance

0.223 L/day.

ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Amg 827.Approved
FingolimodAmg 827 may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Amg 827 is combined with G17DT.Investigational
INGN 201The risk or severity of adverse effects can be increased when Amg 827 is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Amg 827 is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Amg 827 is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Amg 827 is combined with Natalizumab.Approved, Investigational
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Amg 827.Approved, Investigational
RindopepimutThe risk or severity of adverse effects can be increased when Amg 827 is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Amg 827.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Amg 827.Approved
SRP 299The risk or severity of adverse effects can be increased when Amg 827 is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Amg 827.Approved, Investigational
TofacitinibAmg 827 may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the neutropenic activities of Amg 827.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. article [Link]
  2. article [Link]
External Links
ATC CodesL04AC12
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailablePsoriasis1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPsoriasis2
1WithdrawnBasic ScienceAsthma Bronchial1
1, 2CompletedTreatmentRheumatoid Arthritis1
2CompletedTreatmentAsthma Bronchial1
2CompletedTreatmentModerate to Severe Plaque Psoriasis1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis1
2TerminatedTreatmentAsthma Bronchial1
2TerminatedTreatmentCrohn's Disease (CD)2
2TerminatedTreatmentPsoriasis1
2TerminatedTreatmentPsoriatic Arthritis1
2TerminatedTreatmentRheumatoid Arthritis1
2WithdrawnTreatmentSpondyloarthritis, Axial1
3Active Not RecruitingTreatmentModerate to Severe Plaque Psoriasis1
3CompletedTreatmentPsoriasis2
3CompletedTreatmentPsoriasis Vulgaris / Psoriatic Arthritis / Psoriatic Erythroderma / Pustular Psoriasis / Pustular; Psoriasis, Palmaris Et Plantaris1
3CompletedTreatmentPsoriatic Arthritis1
3RecruitingTreatmentSpondyloarthritis, Axial1
3TerminatedTreatmentModerate to Severe Plaque Psoriasis3
3TerminatedTreatmentPsoriasis1
3TerminatedTreatmentPsoriatic Arthritis1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
InjectionSubcutaneous210 mg/1
PricesNot Available
PatentsNot Available
Properties
StateNot Available
Experimental PropertiesNot Available
Taxonomy
DescriptionNot Available
KingdomOrganic Compounds
Super ClassOrganic Acids
ClassCarboxylic Acids and Derivatives
Sub ClassAmino Acids, Peptides, and Analogues
Direct ParentPeptides
Alternative ParentsNot Available
SubstituentsNot Available
Molecular FrameworkNot Available
External DescriptorsNot Available
Drug created on October 20, 2016 14:47 / Updated on March 08, 2017 14:30